He   a biotech company, Agensys, which was acquired by a bigger company for more than $500 million. He was also involved with Cougar Biotechnology, which developed the prostate cancer drug Zytiga and was acquired by Johnson   Johnson for $1 billion in May 2009. A month later, Dr. Belldegrun formed Kite with a group of colleagues and investors to pursue cancer immunotherapy. 